Most scaling plans for clinical research in Africa describe expansion. Fewer describe integration.
Expansion adds sites, countries, investigators, and trials. Integration is the harder work of making those additions function as a single operational system. The continent’s clinical research future will be shaped less by how many sites it adds over the next decade than by how well the sites it has are connected, standardized, and governed.
What Growth Without Integration Actually Produces
Expansion fails when growth outpaces system integration, standardization, and delivery oversight. We have seen this play out globally. Recent frameworks for assessing clinical trial site readiness show that operational readiness extends far beyond physical infrastructure (1). It depends on procedural consistency, quality oversight, and the ability to operate predictably across sites.
That distinction matters. A network can add sites quickly and still remain operationally fragile if those sites do not work in the same way, produce comparable data, or operate under a shared governance structure.
What Integration Requires in Practice
The first layer is standardized operating procedures. Core trial activities, from consent and sample collection to source documentation and adverse event reporting, should be performed the same way within a network. Without shared Standard Operating Procedures (SOPs), a sponsor cannot assume that data from one site will be directly comparable with data from another. Standardization is a basic requirement of scientific credibility.
The second layer is data architecture. Multi-site trials should not depend on custom, one-off integration every time a new site is added. Networks need common data dictionaries, interoperable interfaces with sponsor systems, and shared quality oversight tools. When data architecture is unified, cross-country work becomes easier to manage. When it is fragmented, the network becomes a set of disconnected projects rather than a single system.
The third layer is governance. Written committees, clear charters, and defined decision rights must continue to function when personnel change. The hidden governance gap identified in recent industry analysis is especially relevant here: without governance, multi-site systems become dependent on the people currently in the room (2). Networks that fail to invest in governance usually discover the gap only when a trial is already under way.
The fourth layer is regulatory and contracting integration. Sponsors are more likely to support multi-country African trials when they can submit through clearer pathways, contract through fewer handoffs, and receive more coordinated regulatory review. The February 2025 work-sharing agreement among Africa’s leading national medicines regulatory authorities (3), alongside emerging reliance pathways linked to the African Medicines Agency (AMA) (4), are important steps in that direction.
What Other Regions Teach About Scaling
Singapore provides a useful case study in slow, deliberate integration. Assessments of Singapore’s biomedical cluster describe more than two decades of coordinated investment in a single ecosystem built around infrastructure, talent, translational research, and manufacturing policy (5). The result is an environment where quality and reliability are built into the system rather than added later.
China shows a different lesson. Before 2015, the system had scale but weaker coordination. Subsequent reforms reshaped drug review pathways and supported more functional multi-regional trial frameworks (6)
India offers a similar lesson. Rapid growth in earlier years was followed by regulatory resets and reforms that improved predictability but also required the industry to adapt to a changed operating environment (7).
The lesson is clear: scale without integration creates fragility, integration without scale remains limited, and scale paired with integration creates durable research systems.
What African Scaling Should Look Like
For African clinical research, the mandate is to grow at the speed at which networks can actually integrate, not at the speed at which they can announce expansion.
That means writing continental SOPs once and using them consistently, adopting a common data architecture, and sustaining regulatory engagement with continental bodies such as the AMA. At ACRN, our working position is simple: credible scale follows integration. Africa’s clinical research future will be shaped not just by how many sites exist, but by how well those sites work together as a system.
The systems that compound over time are the systems that integrate well.
References
- Buse JB, Austin CP, Johnston SC, Lewis-Hall F, March AN, Shore CK, et al. A framework for assessing clinical trial site readiness. J Clin Transl Sci. 2023 Jan;7(1):e151. doi:10.1017/cts.2023.541
- The Hidden Governance Gap in Modern Clinical Trials. DIA Global Forum [Internet]. 2026 Feb 27 [cited 2026 Jun 23]. Available from: https://globalforum.diaglobal.org/issue/march-2026/the-hidden-governance-gap-in-modern-clinical-trials/
- Landmark Agreement Among Africa’s Leading National Medicines Regulatory Authorities to Foster Collaboration. Africa CDC [Internet]. [cited 2026 Jun 23]. Available from: https://africacdc.org/news-item/landmark-agreement-among-africas-leading-national-medicines-regulatory-authorities-to-foster-collaboration/
- African Medicines Agency – Improving access to quality,safeand efficacious medical products for the continent. [Internet]. [cited 2026 Jun 23]. Available from: https://au-ama.africa/
- Singapore’s biomedical cluster: Lessons from two decades of innovation and manufacturing policy. Cambridge Industrial Innovation Policy [Internet]. [cited 2026 Jun 23]. Available from: https://www.ciip.group.cam.ac.uk/reports-and-articles/singapores-biomedical-cluster-lessons-from-two-decades-of-innovation-and-manufacturing-policy/
- Su L, Liu S, Li G, Xie C, Yang H, Liu Y, et al. Trends and Characteristics of New Drug Approvals in China, 2011–2021. TherInnovRegul Sci. 2023 Mar 1;57(2):343–51. doi:10.1007/s43441-022-00472-3
- SariolaS, Jeffery R,Jesani A, Porter G. How Civil Society Organisations Changed the Regulation of Clinical Trials in India. Sci Cult. 2018 Jul 13;28(2):200–22. doi:10.1080/09505431.2018.1493449 PubMed PMID: 31391707; PubMed Central PMCID: PMC6636898.